HealthEquity (NASDAQ:HQY) Rating Increased to Buy at Wall Street Zen

Wall Street Zen upgraded shares of HealthEquity (NASDAQ:HQY) from a hold rating to a buy rating in a report published on Saturday morning.

Other analysts also recently issued research reports about the company. BMO Capital Markets raised HealthEquity from a “market perform” rating to an “outperform” rating and raised their price target for the stock from $85.00 to $105.00 in a report on Thursday, April 9th. BTIG Research upped their price objective on HealthEquity from $110.00 to $115.00 and gave the stock a “buy” rating in a research note on Friday. Royal Bank Of Canada increased their target price on HealthEquity from $100.00 to $108.00 and gave the stock an “outperform” rating in a research report on Wednesday, June 3rd. Citigroup reiterated a “market outperform” rating on shares of HealthEquity in a research note on Monday, June 1st. Finally, Weiss Ratings raised shares of HealthEquity from a “hold (c)” rating to a “hold (c+)” rating in a report on Friday, June 5th. Eleven research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus price target of $110.93.

HealthEquity Price Performance

HQY opened at $94.64 on Friday. The firm has a market cap of $7.91 billion, a price-to-earnings ratio of 35.45, a price-to-earnings-growth ratio of 1.59 and a beta of 0.21. HealthEquity has a fifty-two week low of $72.76 and a fifty-two week high of $105.96. The company’s 50-day moving average price is $90.21 and its 200 day moving average price is $84.94. The company has a quick ratio of 3.44, a current ratio of 3.44 and a debt-to-equity ratio of 0.46.

HealthEquity (NASDAQ:HQY) last issued its earnings results on Thursday, May 28th. The company reported $1.24 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.11 by $0.13. The firm had revenue of $354.64 million for the quarter, compared to analysts’ expectations of $352.02 million. HealthEquity had a net margin of 17.25% and a return on equity of 14.75%. The company’s quarterly revenue was up 7.2% compared to the same quarter last year. HealthEquity has set its FY 2027 guidance at 2.880-2.950 EPS. As a group, sell-side analysts expect that HealthEquity will post 3.92 earnings per share for the current year.

Insider Transactions at HealthEquity

In other HealthEquity news, Director Gayle Furgurson Wellborn sold 2,439 shares of HealthEquity stock in a transaction on Thursday, May 28th. The stock was sold at an average price of $90.00, for a total transaction of $219,510.00. Following the sale, the director owned 19,733 shares of the company’s stock, valued at $1,775,970. The trade was a 11.00% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, EVP Michael Henry Fiore sold 3,142 shares of the business’s stock in a transaction on Friday, May 29th. The stock was sold at an average price of $95.00, for a total value of $298,490.00. Following the transaction, the executive vice president owned 59,113 shares of the company’s stock, valued at $5,615,735. This trade represents a 5.05% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last three months, insiders sold 17,905 shares of company stock worth $1,651,280. Company insiders own 1.60% of the company’s stock.

Institutional Inflows and Outflows

A number of large investors have recently modified their holdings of the business. Sivia Capital Partners LLC acquired a new position in HealthEquity during the 2nd quarter valued at about $306,000. Arrowstreet Capital Limited Partnership bought a new stake in shares of HealthEquity during the 2nd quarter worth about $4,747,000. Marshall Wace LLP acquired a new stake in shares of HealthEquity in the 2nd quarter worth approximately $5,483,000. Amundi lifted its stake in shares of HealthEquity by 9.3% in the 2nd quarter. Amundi now owns 30,203 shares of the company’s stock worth $3,059,000 after acquiring an additional 2,574 shares during the period. Finally, Jump Financial LLC bought a new position in shares of HealthEquity in the second quarter valued at approximately $449,000. 99.55% of the stock is owned by institutional investors and hedge funds.

About HealthEquity

HealthEquity, Inc (NASDAQ: HQY) is a leading administrator of consumer-directed health accounts and related benefit solutions in the United States. Founded in 2002 and headquartered in Draper, Utah, the company specializes in health savings accounts (HSAs) and offers complementary services such as flexible spending accounts (FSAs), health reimbursement arrangements (HRAs), COBRA administration and commuter benefits. Through its technology-driven platform, HealthEquity enables employers, health plans and individuals to streamline account management, improve cost transparency and encourage more informed healthcare spending.

Serving millions of members across all 50 states, HealthEquity leverages an open-architecture ecosystem that integrates with health plans, payroll providers and financial institutions.